Unit economics
The brief's margin ranges are not wrong; they are quoted on the measure that flatters. Read as gross margin they are broadly defensible, and read as operating margin none of them is reachable at any tier.
The cost stack for the module line, which is the middle of the three:
- Share of revenue
- 44%
- Basis
- Substrate film, conductor, gold and silver/silver chloride, bonded die, passives. Materials-heavy is characteristic of the tier: polyimide film alone is quoted at 60% to 70% of operating cost in flexible-circuit plants
- Share of revenue
- 19%
- Basis
- Labor, cleanroom operation, yield loss
- Share of revenue
- 9%
- Basis
- Depreciation and share of the roll-to-roll and cleanroom asset base
- Share of revenue
- 72%
- Share of revenue
- 28%
Gross margin by line, and the blend that follows from the 2032 mix:
- Gross margin
- 22%
- Basis
- Priced against incumbent converters with no product differentiation. Below Integer's 27.0% because this is the most commoditized tier
- Gross margin
- 28%
- Basis
- The stack above
- Gross margin
- 48%
- Basis
- Qualification cost and switching cost support price. Below Dexcom's 60.1%, which is a brand owner's margin rather than a supplier's
- Gross margin
- 26.1%
- Basis
- From the mix, not assumed
Operating expense splits into a part that scales and a part that does not. The fixed organization runs $14M in 2027 rising to $36M in 2032: quality, regulatory affairs, and a technical sales force. At a fully loaded $180,000 a head that is about 78 people at the start and 200 at the end, which is what a medical quality system and a technical sales organization for three product lines require. Variable operating expense runs 6% of revenue. The fixed part is what makes the early years lose money, because it exists before there is revenue to carry it.
That produces an operating margin of -1.7% in 2032, and no operating profit in any year of the horizon.
The brief's margin ranges
The brief's stated ranges were 10% to 15% for standard substrate, up to 40% for customized substrate, and 30% to 60% for modules and components. It does not say which measure they are on, and that omission is doing most of the work.
Read as gross margin, they are broadly defensible. Integer earns 27.0% gross across this kind of work, Dexcom 60.1%, and this analysis models the interventional line at 48% gross. A 30% to 60% gross margin on a differentiated component is a real thing, and the customized-substrate figure of up to 40% sits comfortably inside what the interventional tier supports.
Read as operating margin, none of them is reachable at any tier. The largest merchant operator in this industry earns 11.9%. The brand owner that holds the clearance, the IP and the payer relationship earns 19.6%. A component supplier earning 30% operating would be out-earning both, which nothing here supports.
That distinction is the answer to the brief's question, and it is also why the memo's own blend lands at 26.1% gross and -1.7% operating. The ranges are not wrong; they are quoted on the measure that flatters, while the target is set on the measure that does not.